185 related articles for article (PubMed ID: 37543185)
41. Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease.
Cavagnero K; Doherty TA
J Cytokine Biol; 2017 Aug; 2(2):. PubMed ID: 28959799
[TBL] [Abstract][Full Text] [Related]
42. The role of aspirin desensitization in patients with aspirin-exacerbated respiratory disease (AERD).
Spies JW; Valera FC; Cordeiro DL; de Mendonça TN; Leite MG; Tamashiro E; Arruda LK; Anselmo-Lima WT
Braz J Otorhinolaryngol; 2016; 82(3):263-8. PubMed ID: 26601997
[TBL] [Abstract][Full Text] [Related]
43. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
44. Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose.
Laidlaw TM; Chu DK; Stevens WW; White AA
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1462-1467. PubMed ID: 34999274
[TBL] [Abstract][Full Text] [Related]
45. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.
Steinke JW; Liu L; Huyett P; Negri J; Payne SC; Borish L
J Allergy Clin Immunol; 2013 Oct; 132(4):856-65.e1-3. PubMed ID: 23806637
[TBL] [Abstract][Full Text] [Related]
46. Cortactin expression in nasal polyps of Aspirin-Exacerbated Respiratory Disease (AERD) patients.
Brescia G; Parrino D; Nicolè L; Zanotti C; Lanza C; Barion U; Marino F; Marioni G
Am J Otolaryngol; 2018; 39(3):293-298. PubMed ID: 29534838
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.
Rajan JP; Wineinger NE; Stevenson DD; White AA
J Allergy Clin Immunol; 2015 Mar; 135(3):676-81.e1. PubMed ID: 25282015
[TBL] [Abstract][Full Text] [Related]
48. Algorithmic Identification of Patients With Aspirin-Exacerbated Respiratory Disease Using an Electronic Health Record.
Tao M; Roberts S; Arnold M
Otolaryngol Head Neck Surg; 2023 Aug; 169(2):253-257. PubMed ID: 36939473
[TBL] [Abstract][Full Text] [Related]
49. Prostaglandin E2 receptors in asthma and in chronic rhinosinusitis/nasal polyps with and without aspirin hypersensitivity.
Machado-Carvalho L; Roca-Ferrer J; Picado C
Respir Res; 2014 Aug; 15(1):100. PubMed ID: 25155136
[TBL] [Abstract][Full Text] [Related]
50. Endocannabinoid receptor CB2R is significantly expressed in aspirin-exacerbated respiratory disease: a pilot study.
Corrado A; Battle M; Wise SK; Lee FE; Guidot DM; DelGaudio JM; Molina SA; Levy JM
Int Forum Allergy Rhinol; 2018 Oct; 8(10):1184-1189. PubMed ID: 29897665
[TBL] [Abstract][Full Text] [Related]
51. Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.
Cahill KN; Raby BA; Zhou X; Guo F; Thibault D; Baccarelli A; Byun HM; Bhattacharyya N; Steinke JW; Boyce JA; Laidlaw TM
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):34-40. PubMed ID: 26051534
[TBL] [Abstract][Full Text] [Related]
52. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease.
Choi JH; Kim MA; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):1-6. PubMed ID: 24300420
[TBL] [Abstract][Full Text] [Related]
53. Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease.
Takahashi T; Kato A; Berdnikovs S; Stevens WW; Suh LA; Norton JE; Carter RG; Harris KE; Peters AT; Hulse KE; Grammer LC; Welch KC; Shintani-Smith S; Tan BK; Conley DB; Kern RC; Bochner BS; Schleimer RP
J Allergy Clin Immunol; 2017 Sep; 140(3):720-729. PubMed ID: 28238741
[TBL] [Abstract][Full Text] [Related]
54. Association Between Aspirin-Exacerbated Respiratory Disease and Atherosclerotic Cardiovascular Disease: A Retrospective Review of US Claims Data.
Adame MJ; Raji M; Shan Y; Zhang Y; Kuo YF; Tripple JW
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3445-3453.e6. PubMed ID: 37468040
[TBL] [Abstract][Full Text] [Related]
55. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis.
Bochenek G; Kuschill-Dziurda J; Szafraniec K; Plutecka H; Szczeklik A; Nizankowska-Mogilnicka E
J Allergy Clin Immunol; 2014 Jan; 133(1):98-103.e1-6. PubMed ID: 23993879
[TBL] [Abstract][Full Text] [Related]
56. Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.
Cooper T; Greig SR; Zhang H; Seemann R; Wright ED; Vliagoftis H; Côté DWJ
Auris Nasus Larynx; 2019 Aug; 46(4):526-532. PubMed ID: 30577986
[TBL] [Abstract][Full Text] [Related]
57. Inflammatory mediators in nasal secretions of patients with nasal polyposis with and without aspirin sensitivity.
Perić A; Gaćeša D; Cvetković G; Vojvodić D
Immun Inflamm Dis; 2023 Feb; 11(2):e791. PubMed ID: 36840483
[TBL] [Abstract][Full Text] [Related]
58. [Advances in aspirin-exacerbated respiratory disease (AERD)].
Higashi N; Mitsui C; Taniguchi M
Nihon Rinsho; 2016 Oct; 74(10):1683-1687. PubMed ID: 30551280
[TBL] [Abstract][Full Text] [Related]
59. Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Mullur J; Buchheit KM
Ann Allergy Asthma Immunol; 2023 Sep; 131(3):317-324. PubMed ID: 37225000
[TBL] [Abstract][Full Text] [Related]
60. Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD.
Choi GS; Kim JH; Shin YS; Ye YM; Kim SH; Park HS
Clin Exp Allergy; 2013 Jul; 43(7):730-40. PubMed ID: 23786280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
